ANTI-NKG2A ANTIBODIES AND THEIR USES

Description

This description provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that bind specifically to the human natural killer cell group 2A (NKG2A) inhibitory receptor protein with high affinity and exhibit therapeutically desirable functional properties for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. ALSO PROVIDED NUCLEIC ACID MOLECULES THAT ENCODE ANTIBODIES, EXPRESSION VECTORS, HOST CELLS AND TREATMENT METHODS FOR, FOR EXAMPLE, CANCER THAT USE ANTIBODIES.COMBINATION THERAPY, IN WHICH AN ANTI-NKG2A ANTIBODY AS DESCRIPTED HEREIN IS ADMINISTERED IN CONJUNCTION WITH AT LEAST ONE ADDITIONAL AGENT SUCH AS ANOTHER ANTIBODY (FOR EXAMPLE, ANTI-PD-1, ANTI-PD-L1 AND / OR ANTI-CTLA-4 ANTIBODIES), IS ALSO PROVIDED.